Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which reduces repetitive neuronal firing and stabilizes hyperexcitable neuronal networks, thereby decreasing the likelihood of seizure initiation and spread.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosing should follow the prescriber’s instructions and local guidelines.

Lacosamide is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should be used only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it is generally well tolerated, though individual response and side‑effect profiles vary.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Prior to administration, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the clinical protocol.

Lacosamide Fresenius Kabi is given by intravenous infusion. The infusion rate and duration are set by the treating physician, typically based on the patient’s weight, renal function, and clinical response. Administration should follow aseptic technique and institutional infusion guidelines.

Serious adverse events include cardiac arrhythmias such as atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behavior, respiratory depression, and rare cases of anaphylaxis. Prompt medical evaluation is essential if any of these occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction abnormalities, uncontrolled arrhythmias, or severe hepatic impairment. Clinical judgment should guide use in pregnant or breastfeeding women.